论文部分内容阅读
目的观察复方福尔可定口服液治疗婴幼儿喘息性支气管炎的临床疗效。方法将192例婴幼儿喘息性支气管炎患儿随机分为治疗组和对照组,每组96例。两组均给予抗感染、止咳、平喘、雾化吸入等综合治疗。治疗组加入复方福尔可定口服液,比较两组疗效。结果治疗组治愈70例,治愈率为72.92%,好转20例,无效6例,总有效率为93.75%;对照组治愈54例,治愈率为56.25%,好转16例,无效26例,总有效率为77%。结论复方福尔可定口服液治疗婴幼儿喘息性支气管炎安全有效。
Objective To observe the clinical efficacy of Fufang Erding oral liquid in the treatment of infantile asthmatic bronchitis. Methods 192 infants with asthmatic bronchitis were randomly divided into treatment group and control group, 96 cases in each group. Both groups were given anti-infection, cough, asthma, inhalation and other comprehensive treatment. The treatment group was added Fufuketine oral solution, the two groups were compared. Results In the treatment group, 70 cases were cured, the cure rate was 72.92%, improvement in 20 cases and ineffective in 6 cases, the total effective rate was 93.75%. In the control group, 54 cases were cured, the cure rate was 56.25%, improvement in 16 cases and ineffective in 26 cases. Efficiency is 77%. Conclusion Fufang Erding oral solution for asthmatic bronchitis in infants and young children safe and effective.